Quick Answer
Tvardi Therapeutics, Inc. reported Total Revenue of $7.14 million for fiscal year 2024.
Tvardi Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | — | $7.14M -66.0% |
$20.97M -49.9% |
$41.87M +81.8% |
$23.03M -83.0% |
$135.08M +579.3% |
| Revenue (ASC 606) | — | $7.14M -66.0% |
$20.97M -49.9% |
$41.87M +81.8% |
$23.03M -83.0% |
$135.08M +579.3% |
| Net Income | -$18.21M +38.0% |
-$29.40M +75.2% |
-$118.51M -38.7% |
-$85.47M +3.4% |
-$88.44M -1151.6% |
$8.41M +107.9% |
| Diluted EPS | -$3.26 +71.5% |
-$11.42 +56.5% |
-$26.26 -37.3% |
-$19.12 -998.9% |
-$1.74 -1066.7% |
$0.18 +107.2% |
| Total Assets | $32.07M -8.9% |
$35.20M -72.0% |
$125.84M -30.9% |
$182.24M -26.2% |
$247.06M -8.9% |
$271.16M +16.4% |
| Cash and Equivalents | $20.73M -34.4% |
$31.61M -38.9% |
$51.77M -18.8% |
$63.74M +373.8% |
$13.45M -57.5% |
$31.68M +73.1% |
| Stockholders Equity | $20.95M +123.0% |
-$91.13M -46.8% |
-$62.06M -139.1% |
$158.78M -30.2% |
$227.52M -8.6% |
$249.00M +33.4% |
| R&D Expense | $18.01M -23.8% |
$23.65M -78.2% |
$108.51M +18.1% |
$91.88M +11.1% |
$82.70M -23.3% |
$107.85M -5.2% |
| Operating Income | -$26.75M +4.8% |
-$28.11M +76.9% |
-$121.50M -38.8% |
-$87.53M +1.7% |
-$89.08M -1754.3% |
$5.38M +104.8% |
| Shares Outstanding | 9.38M +264.4% |
2.57M -43.3% |
4.54M -91.6% |
53.80M +0.6% |
53.48M +7.2% |
49.87M +6.7% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | March 31, 2025 | $2.57M | +20.3% | +0.5% |
| Revenue (ASC 606) | March 31, 2025 | $2.57M | +20.3% | +0.5% |
| Net Income | September 30, 2025 | -$5.53M | -0.3% | -232.6% |
| Diluted EPS | September 30, 2025 | -$0.59 | +72.4% | +41.0% |
| Total Assets | September 30, 2025 | $39.02M | -24.0% | -10.8% |
| Cash and Equivalents | September 30, 2025 | $21.42M | -42.2% | +3.7% |
| Stockholders Equity | September 30, 2025 | $27.87M | +135.5% | -15.4% |
| R&D Expense | September 30, 2025 | $3.60M | -24.9% | -37.9% |
| Operating Income | September 30, 2025 | -$5.94M | -4.6% | +33.0% |
| Shares Outstanding | September 30, 2025 | 9.38M | -82.9% | +0.1% |
- Tvardi Therapeutics, Inc. reported Total Revenue of $7.14 million for fiscal year 2024.
- Tvardi Therapeutics, Inc. showed a decrease of -66.0% in Total Revenue compared to the prior fiscal year.
- Tvardi Therapeutics, Inc. reported Revenue (ASC 606) of $7.14 million for fiscal year 2024.
- Tvardi Therapeutics, Inc. showed a decrease of -66.0% in Revenue (ASC 606) compared to the prior fiscal year.
- Tvardi Therapeutics, Inc. reported Net Income of -$18.21 million for fiscal year 2025.
- Tvardi Therapeutics, Inc. showed an increase of +38.0% in Net Income compared to the prior fiscal year.
- Tvardi Therapeutics, Inc. reported Diluted EPS of $3.26 per share (loss) for fiscal year 2025.
- Tvardi Therapeutics, Inc. showed an increase of +71.5% in Diluted EPS compared to the prior fiscal year.
- Tvardi Therapeutics, Inc. reported Total Assets of $32.07 million for fiscal year 2025.
- Tvardi Therapeutics, Inc. showed a decrease of -8.9% in Total Assets compared to the prior fiscal year.
- Tvardi Therapeutics, Inc. reported Cash and Equivalents of $20.73 million for fiscal year 2025.
- Tvardi Therapeutics, Inc. showed a decrease of -34.4% in Cash and Equivalents compared to the prior fiscal year.
- Tvardi Therapeutics, Inc. reported Stockholders Equity of $20.95 million for fiscal year 2025.
- Tvardi Therapeutics, Inc. showed an increase of +123.0% in Stockholders Equity compared to the prior fiscal year.
- Tvardi Therapeutics, Inc. reported R&D Expense of $18.01 million for fiscal year 2025.
- Tvardi Therapeutics, Inc. showed a decrease of -23.8% in R&D Expense compared to the prior fiscal year.
- Tvardi Therapeutics, Inc. reported Operating Income of -$26.75 million for fiscal year 2025.
- Tvardi Therapeutics, Inc. showed an increase of +4.8% in Operating Income compared to the prior fiscal year.
- Tvardi Therapeutics, Inc. reported Shares Outstanding of 9.38 million shares for fiscal year 2025.
- Tvardi Therapeutics, Inc. showed an increase of +264.4% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: